Cambridge Investment Research Advisors
PCRX icon

Cambridge Investment Research Advisors’s Pacira BioSciences PCRX Stock Holding History

Cambridge Investment Research Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.77M Buy
122,762
+17,617
+17% +$392K 0.01% 1341
2025
Q4 		$2.72M Buy
+105,145
New +$2.5M 0.01% 1291
2020
Q3 		– Sell
-4,420
Closed -$232K – 2579
2020
Q2 		$232K Sell
4,420
-3,608
-45% -$151K ﹤0.01% 2075
2020
Q1 		$269K Buy
8,028
+2,450
+44% +$102K ﹤0.01% 1737
2019
Q4 		$253K Sell
5,578
-1,026
-16% -$43.6K ﹤0.01% 2024
2019
Q3 		$251K Buy
6,604
+185
+3% +$7.38K ﹤0.01% 1953
2019
Q2 		$279K Hold
6,419
– – ﹤0.01% 1781
2019
Q1 		$244K Buy
6,419
+447
+7% +$17.4K ﹤0.01% 1941
2018
Q4 		$257K Sell
5,972
-651
-10% -$30.4K ﹤0.01% 1760
2018
Q3 		$326K Buy
+6,623
New +$286K ﹤0.01% 1742

Other funds holding PCRX

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $761B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return